Business Description
Coherus BioSciences Inc
NAICS : 541714
SIC : 2836
ISIN : US19249H1032
Description
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.36 | |||||
| Equity-to-Asset | -0.17 | |||||
| Debt-to-Equity | -3.07 | |||||
| Debt-to-EBITDA | 7.24 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -3.03 | |||||
| Beneish M-Score | -3.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -21.7 | |||||
| Future 3-5Y Total Revenue Growth Rate | 12.56 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 78.08 | |||||
| 9-Day RSI | 75.03 | |||||
| 14-Day RSI | 70.32 | |||||
| 6-1 Month Momentum % | -61.52 | |||||
| 12-1 Month Momentum % | -66.52 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | |||||
| Quick Ratio | 1.09 | |||||
| Cash Ratio | 0.33 | |||||
| Days Inventory | 130.66 | |||||
| Days Sales Outstanding | 264.81 | |||||
| Days Payable | 90.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.7 | |||||
| Shareholder Yield % | 73.14 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 44.71 | |||||
| Operating Margin % | -45.45 | |||||
| Net Margin % | -0.15 | |||||
| FCF Margin % | -19.82 | |||||
| ROA % | -0.07 | |||||
| ROIC % | -63.8 | |||||
| ROC (Joel Greenblatt) % | 119.17 | |||||
| ROCE % | 12.41 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Price-to-Owner-Earnings | 14.02 | |||||
| PS Ratio | 0.47 | |||||
| EV-to-EBIT | 9.78 | |||||
| EV-to-Forward-EBIT | 5.21 | |||||
| EV-to-EBITDA | 8.39 | |||||
| EV-to-Forward-EBITDA | 5.15 | |||||
| EV-to-Revenue | 1.03 | |||||
| EV-to-Forward-Revenue | 1.05 | |||||
| EV-to-FCF | -5.04 | |||||
| Earnings Yield (Greenblatt) % | 10.22 | |||||
| FCF Yield % | -44.12 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Coherus BioSciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 278.958 | ||
| EPS (TTM) (€) | -0.07 | ||
| Beta | 0 | ||
| Volatility % | 76.28 | ||
| 14-Day RSI | 70.32 | ||
| 14-Day ATR (€) | 0.05441 | ||
| 20-Day SMA (€) | 0.887895 | ||
| 12-1 Month Momentum % | -66.52 | ||
| 52-Week Range (€) | 0.6062 - 3.335 | ||
| Shares Outstanding (Mil) | 115.21 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Coherus BioSciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Coherus BioSciences Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Coherus BioSciences Inc Frequently Asked Questions
What is Coherus BioSciences Inc(FRA:8C5)'s stock price today?
The current price of FRA:8C5 is €1.20. The 52 week high of FRA:8C5 is €3.34 and 52 week low is €0.61.
When is next earnings date of Coherus BioSciences Inc(FRA:8C5)?
The next earnings date of Coherus BioSciences Inc(FRA:8C5) is 2025-03-13 Est..
Does Coherus BioSciences Inc(FRA:8C5) pay dividends? If so, how much?
Coherus BioSciences Inc(FRA:8C5) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers